Merck & Co., Inc. vs Utilities Select Sector SPDR Fund — how do they compare? Merck & Co., Inc. trades at $142.58 (market cap $351.28B), while Utilities Select Sector SPDR Fund trades at $41.15 (market cap $23.60B). The key difference: Merck & Co., Inc. is far larger — about 14.9× Utilities Select Sector SPDR Fund's market cap, and Merck & Co., Inc. pays a 2.39% dividend while Utilities Select Sector SPDR Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Utilities Select Sector SPDR Fund for 80 Days on average.
| MRK | XLU | |
|---|---|---|
Market Cap | $351.28B | $23.60B |
Volume | 7,969,665 | 28,758,237 |
Sector | Health | — |
52-Week High | $156.43 | $47.73 |
52-Week Low | $82.49 | $39.25 |
Typical Hold Time | 98 Days | 80 Days |
Enterprise Value | $398.04B | — |
Dividend Yield | 2.39% | — |
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $142.79, up 0.61% on the day, with a bearish technical signal despite beating earnings estimates in recent quarters. The company reported 2025 revenue of $65.01B and net income of $18.25B, with a high P/E ratio of 113.9 reflecting premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while institutional investors have been increasing stakes.
The outlook is mixed: strong analyst consensus (68% buy ratings) and a $158.78 price target suggest upside, but high valuation and bearish technicals pose near-term risks. Key opportunities include pipeline expansion via M&A; risks involve integration challenges and patent pressures.
XLU trades at $41.15, down slightly by 0.02% with mixed technical signals showing a bullish moving average trend but neutral oscillators. The ETF recently hit 52-week lows amid sector-wide pressure from rising interest rates. Recent news highlights utility stocks as oversold with potential defensive appeal during market volatility.
The outlook remains cautious due to interest rate sensitivity, though oversold conditions may present opportunity for defensive positioning. Key risks include continued rate hikes and regulatory pressures, while potential upside exists if utilities regain favor as AI power demand grows.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: electric utilities; water utilities; multi-utilities; independent power and renewable electricity producers; and gas utilities. The fund is non-diversified.
Read more on XLU →